Page 38 - 2021_12-Haematologica-web

L. Zalmai et al.
Table 1. Clinical and biological features of the cohort.
Patient Age Sex Material WHO FAB Secondary Prior Extramedullar Anatomopathology Karyotype FISH pDC
number (y)
N13 87 F
N16* 59 M N2 77 M
N20 71 M
N19 70 F N8 64 M
N1 82 F N9$ 70 M
N11 68 M
N7 79 M
N12 55 M N36 52 M
N14 85 M
N34¤ 73 M N35 65 M
classification classification (yes/no) therapy lesions ofextramedullar lesions
KMT2A contingent (11q23)
PB AML with mutated
RUNX1
BM AML-MRC
BM AML with mutated RUNX1
BM AML with mutated
RUNX1
BM AML with mutated
RUNX1
BM AML with KMT2A(MLL)
rearrangement and mutated RUNX1
M0 AML no
M0 AML no M0 AML no
M0 AML no
M0 AML no M0 AML no
M0 AML no
M0 AML Neutropenia and
thrombocytopenia, monitoring granulocytic
46,XX[20]
46,XY,del(7) (q36)[8]/46,XY[12] 46,XY
45,X,-Y[20]
46,XX[20] 46,XY[20]
no anomaly detected ND
CD34–
CD34– CD34–
CD34–
CD34+ CD34–
CD34+ CD34+
CD34+
CD34–
no
no yes/cutaneous
no
no
yes/ cutaneous
ND
ND AML
ND
ND AML
no anomaly detected no anomaly detected no anomaly detected rearranged
no anomaly
detected ND
no anomaly detected
PB AML with mutated RUNX1
BM AML-MRC
BM AML with mutated
RUNX1
BM AMLwith mutated
RUNX1
BM AML with mutated
RUNX1
BM AML without maturation
BM AML-MRC
PB AML-MRC BM AML with
mutated NPM1
and KMT2A(MLL)
rearrangement
no ND 47,XX,+13[13] /46,XX[7]
Therapeutic abstention, cutaneous
yes/ pDCs
46,X,-Y,+13 [11]/46,XY[23]
dysplasia£ M0 AML no
M0AML no
yes/ pDCs
cutaneous [21]/46,XY[11]
yes/ ND lymph nodes
no ND no ND
Therapeutic no ND abstention,
monitoring
Hydroxyurea no ND Therapeutic no ND
abstention, monitoring
46,XY ND
47,XY,+13
M0 AML M1 AML
M4 AML
M4 AML M5 AML
no no
CMML
CMML MDS/MPN
46,XY[30] 46,XY[28]
46,XY,-7,+mar [18]/46,XY[4]
46,XY[20] 46,XY[20]
no CD34+ anomaly
detected
no CD34+
anomaly detected
ND CD34+
ND CD34– rearranged CD34–
BM: bone marrow; PB: peripheral blood; AML-MRC: AML with myelodysplasia-related changes; WHO classification: World Health Organization classification; FAB: French- American-British classification; FISH: fluorescent in situ hybridization; ND: not done; F: female; M: male. $pDC nodules were described on BM biopsy. £Diagnosis of myelodysplasia was not clearly affirmed before acute myeloid leukemia (AML) state. ¤Only patient N34 experienced a prior history of solid tumor with prostatic neoplasm treated by hor- monotherapy.
3058
haematologica | 2021; 106(12)